We highlight two interesting candidates for drug repurposing opportunities that could be investigated for schizophrenia treatment: lanoteplase, which targets laminins and is currently used in the treatment of myocardial infarction; and felbamate, an NMDA receptor inhibitor used to treat severe epilepsy. Here, LAMB2 is linked to myocardial infarction.